Sensei Biotherapeutics, Inc. (NASDAQ:SNSE – Get Free Report) major shareholder Millennium Management Llc sold 7,666 shares of the firm’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $32.12, for a total value of $246,231.92. Following the completion of the transaction, the insider owned 144,974 shares in the company, valued at $4,656,564.88. The trade was a 5.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Millennium Management Llc also recently made the following trade(s):
- On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $28.12, for a total value of $52,218.84.
- On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.81, for a total value of $13,539.05.
- On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.61, for a total value of $23,629.68.
- On Monday, March 30th, Millennium Management Llc acquired 9,533 shares of Sensei Biotherapeutics stock. The stock was acquired at an average cost of $25.86 per share, for a total transaction of $246,523.38.
- On Friday, March 27th, Millennium Management Llc acquired 15,321 shares of Sensei Biotherapeutics stock. The stock was acquired at an average cost of $26.61 per share, for a total transaction of $407,691.81.
- On Thursday, March 26th, Millennium Management Llc acquired 5,731 shares of Sensei Biotherapeutics stock. The stock was acquired at an average cost of $28.62 per share, for a total transaction of $164,021.22.
- On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $25.49, for a total value of $40,554.59.
- On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $31.65, for a total value of $36,397.50.
- On Wednesday, April 1st, Millennium Management Llc acquired 6,175 shares of Sensei Biotherapeutics stock. The stock was acquired at an average cost of $34.49 per share, for a total transaction of $212,975.75.
- On Tuesday, March 31st, Millennium Management Llc purchased 6,005 shares of Sensei Biotherapeutics stock. The shares were purchased at an average cost of $28.16 per share, for a total transaction of $169,100.80.
Sensei Biotherapeutics Stock Up 3.1%
Shares of SNSE stock traded up $0.61 during mid-day trading on Friday, reaching $20.43. 40,084 shares of the stock traded hands, compared to its average volume of 223,112. The stock’s fifty day simple moving average is $29.11 and its two-hundred day simple moving average is $17.85. Sensei Biotherapeutics, Inc. has a 1-year low of $5.25 and a 1-year high of $36.76. The company has a market cap of $27.40 million, a price-to-earnings ratio of -1.23 and a beta of -0.18.
Analyst Ratings Changes
A number of research firms recently commented on SNSE. Leerink Partners began coverage on Sensei Biotherapeutics in a research note on Monday, April 20th. They issued an “outperform” rating and a $50.00 price objective on the stock. Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Friday, April 24th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $40.00.
View Our Latest Stock Analysis on Sensei Biotherapeutics
Key Headlines Impacting Sensei Biotherapeutics
Here are the key news stories impacting Sensei Biotherapeutics this week:
- Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
- Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release
Institutional Investors Weigh In On Sensei Biotherapeutics
A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC boosted its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE – Free Report) by 10.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 11,516 shares of the company’s stock after purchasing an additional 1,100 shares during the quarter. Renaissance Technologies LLC owned about 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent quarter. 10.50% of the stock is owned by institutional investors and hedge funds.
About Sensei Biotherapeutics
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.
The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.
Featured Articles
- Five stocks we like better than Sensei Biotherapeutics
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
